Nilotinib (TasignaÒ, Novartis Pharmaceuticals UK Ltd) is a second generation TKI. It is more effective than imatinib, because it can inhibit several imatinib‑resistant BCR-ABL1 mutations.
Nilotinib is approved for:
- Patients in the chronic phase with newly-diagnosed CML
- Patients in chronic or accelerated CML phases, who are resistant or intolerant to treatment with previous tried TKIs
